Moreover, TGFBR2 inhibition reverses this immunosuppressive tumor cell phenotype by reducing CD8+ T cell exhaustion and enhancing CD4+ and CD8+ T cell-mediated tumor cell killing. The gene discussed is CD8A; the disease is neoplasm.